Program Description
In hormone receptor–positive/HER2-negative (HR+/HER2−) metastatic breast cancer, progression after first-line endocrine therapy plus cyclin-dependent kinase (CDK) 4/6 inhibition is common. The postprogression landscape often becomes complex, as it depends on the disease mutation status and the patient’s experience with adverse effects. These factors affect treatment decision-making between endocrine-based options, targeted therapies, antibody-drug conjugates, or chemotherapy. Oral selective estrogen receptor degraders (SERDs) have emerged as a distinct class of endocrine therapy for patients with HR+/HER2− metastatic breast cancer, and evidence increasingly supports their role in ESR1-mutated, endocrine-sensitive disease after CDK4/6 progression. However, many health plans lack clear frameworks for the role of oral SERDs, and inconsistent prior authorization criteria drive variability in access. This activity examines the biology behind oral SERDs and equips managed care professionals and pharmacists to translate clinical evidence and real-world data into biomarker-linked coverage criteria, treatment sequencing considerations, and prior authorization standards.
Target audience: Oncology Pharmacists
Type of activity: Application
Release date: November 13, 2026
Expiration date: January 12, 2027
Time to complete activity: 1 hour
Learner level: Foundational, Intermediate, Advanced
Fee: Free
Educational Objectives
At the completion of this activity, pharmacists will be able to:
- Examine the changing treatment options for hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer, including endocrine resistance biology and the mechanisms of action of oral selective estrogen receptor degraders (SERDs), to understand their influence on patient experience, health care delivery, and overall disease burden
- Apply clinical trial data, real-world evidence, and guidelines on oral SERDs to treatment choices and sequencing in HR+/HER2− metastatic breast cancer
- Determine managed care strategies that include pathway placement, biomarker-linked coverage criteria, prior authorization considerations, and monitoring expectations to optimize oral SERD use, enhance quality of care, and promote sustainable resource utilization
Allison R. Butts, PharmD, BCOP
Oncology Pharmacist Manager
Breast Oncology Clinical Specialist
UK HealthCare Markey Cancer Center
Lexington, KY
Accreditation Information
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This application-based activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-26-340-L01-P. The activity is available for CE credit through January 12, 2027.
Obtaining Credit
All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Allison R. Butts, PharmD, BCOP, has no relevant financial relationships with ineligible companies to disclose.
The staff of Pharmacy Times Continuing Education™ have no relevant financial relationships with ineligible companies.
At least 1 anonymous peer reviewer has been used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms